A tsRNA biomarker for diagnosis of hepatocellular carcinoma and its application
Through high-throughput sequencing screening and verification, the tsRNA biomarker tRF-3a-Pro with diagnostic value was obtained for early diagnosis of hepatocellular carcinoma, solving the problem of expensive diagnostic equipment and low marker sensitivity in the prior art. , achieving high sensitivity and specific diagnostic effects.
Patent Information
- Application Number
- CN202410527529.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-29
AI Technical Summary
The prior art relies on expensive and invasive equipment in the early diagnosis of hepatocellular carcinoma, lacks sensitivity and accuracy of blood markers, and lacks effective novel diagnostic markers.
High-throughput sequencing screens high-expression tsRNA in tissues and serum of HCC patients, and obtains tsRNA with diagnostic value after verification. TRF-3a-Pro is used as a biomarker of hepatocellular carcinoma, and a real-time quantitative fluorescent PCR kit is developed to detect it. Expression level.
It has achieved high sensitivity and specific diagnosis of hepatocellular carcinoma, and has important clinical value in promoting and application, and provides a new blood marker that is easy to promote.
Smart Images

Figure CN118326039B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a tsRNA biomarker for diagnosing hepatocellular carcinoma and an application thereof. Background Art
[0002] Primary liver cancer (PLC) is currently the fourth most common malignant tumor and the second leading cause of cancer-related death in my country, seriously threatening the lives and health of the Chinese people. Among them, hepatocellular carcinoma (HCC) accounts for 85% to 90%. With the improvement of diagnostic and treatment technologies, HCC prevention and treatment has made great progress. However, due to the insidious onset and rapid progression of HCC, most cases are already in the middle and late stages when diagnosed. Therefore, early screening and diagnosis of HCC have become the key to improving the prognosis of HCC patients. At present, the early diagnosis of HCC still relies on sophisticated, expensive or invasive instruments and equipment, and clinical HCC blood markers are very limited and their sensitivity and accuracy are unsatisfactory. Therefore, further seeking for better HCC blood markers is currently an urgent need.
[0003] As a kind of ncRNA that has attracted attention in recent years, transfer RNA (tRNA)-derived small RNA (tsRNA) is the product of tRNA cleavage by nuclease under precise regulation. tsRNA has a conserved sequence and a relatively stable structure, and is relatively abundant in body fluids. It is expected to become a new diagnostic marker with potential value for the diagnosis and prognosis of various diseases, especially malignant tumors. Summary of the invention
[0004] The main purpose of the present invention is to provide a tsRNA biomarker for the diagnosis of hepatocellular carcinoma. The tsRNA highly expressed in HCC patient tissues and serum is first screened by high-throughput sequencing, and then the tsRNA with diagnostic value is obtained after population verification, which can be used as a biomarker for the diagnosis of hepatocellular carcinoma.
[0005] Another object of the present invention is to provide the use of the tsRNA biomarker in the preparation of a product for diagnosing hepatocellular carcinoma.
[0006] To achieve the above object, the present invention adopts the following technical solution:
[0007] The present invention provides an application of a tsRNA biomarker for diagnosing hepatocellular carcinoma in preparing a product for diagnosing hepatocellular carcinoma, wherein the tsRNA biomarker is a tRF-3a subtype.
[0008] Preferably, the tsRNA biomarker is tRF-3a-Pro.
[0009] The present invention also provides the use of a reagent for detecting a tsRNA biomarker in preparing a product for diagnosing hepatocellular carcinoma, wherein the tsRNA biomarker is a tRF-3a subtype.
[0010] Preferably, the tsRNA biomarker is tRF-3a-Pro.
[0011] More preferably, the reagent detects the expression level of tRF-3a-Pro in the serum of the subject. When the expression level of tRF-3a-Pro in the serum of the subject is high, it indicates that the subject has a high risk of developing hepatocellular carcinoma.
[0012] The present invention also provides the use of a reagent for detecting the expression level of tRF-3a-Pro in serum in the preparation of a product for diagnosing hepatocellular carcinoma.
[0013] Preferably, the product is a kit.
[0014] More preferably, the kit is a real-time quantitative fluorescent PCR detection kit, comprising a primer pair for detecting tRF-3a-Pro in serum, the sequences of which are shown in SEQ ID NO: 1 and SEQ ID NO: 2, and are as follows:
[0015] Forward:GGGTCCCGGACGAG(SEQ ID NO:1)
[0016] Reverse: CAGTGCGTGTCGTGGAGT (SEQ ID NO: 2).
[0017] More preferably, the kit detects the expression of tRF-3a-Pro in the serum of the subject. When the expression level of tRF-3a-Pro in the serum of the subject is high, it indicates that the subject has a high risk of suffering from hepatocellular carcinoma.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The present invention first screens the tsRNA highly expressed in the tissues and serum of HCC patients through high-throughput sequencing, and then obtains the tsRNA with diagnostic value after population verification. It has been verified that tRF-3a-Pro has good sensitivity and specificity for the diagnosis of liver cancer. It is used as a biomarker for the diagnosis of hepatocellular carcinoma and is detected by classic real-time quantitative fluorescence PCR. It is easy to promote and apply and has important clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1The differential expression analysis of tsRNA in liver cancer and adjacent tissues in the embodiment; (A) principal component analysis of tsRNA expression in liver cancer and adjacent tissues; (B) volcano plot showing 5 pairs of differentially expressed tsRNAs between liver cancer and corresponding adjacent tissues, red represents upregulation and blue represents downregulation; (C) hierarchical clustering heat map of differentially expressed tsRNAs in liver cancer tissues compared with adjacent tissues, red represents upregulation and blue represents downregulation.
[0021] Figure 2 The following are the distribution of tsRNA subtypes in liver cancer and adjacent tissues; (A) distribution of tsRNA subtypes measured in liver cancer tissues and (B) adjacent tissues; (C) distribution of upregulated and (D) downregulated tsRNA subtypes in liver cancer tissues; (E) distribution of upregulated and (F) downregulated tsRNA sources in liver cancer tissues.
[0022] Figure 3 qRT-PCR verification of the expression differences of candidate tsRNAs in liver cancer and adjacent tissues in the example; (A) tRF-3a-Ala-AGC; (B) tRF-3a-Tyr-GTA; (C) tRF-3a-Pro-CGG; (D) tRF-3a-Ala-CGC; (E) tRF-2-Asn-GTT; ns, the difference was not significant, *p<0.05, **p<0.01.
[0023] Figure 4 The expression difference of candidate tsRNA in the serum of liver cancer patients and the control group was verified by qRT-PCR in the example; (A) tRF-3a-Pro-CGG; (B) tRF-3a-Ala-AGC; (C) tRF-3a-Tyr-GTA; (D) tRF-3a-Ala-CGC; ns, no significant difference, *p<0.05.
[0024] Figure 5 Schematic diagrams of different anticodon proline tRNAs in the examples (tRF-3a sequence is marked in red); (A) Schematic diagram of the secondary structure of the tRNA-Pro-AGG sequence; (B) Schematic diagram of the secondary structure of the tRNA-Pro-CGG sequence; (C) Schematic diagram of the secondary structure of the tRNA-Pro-UGG sequence.
[0025] Figure 6 The expression correlation of tRF-3a-Pro in serum and paired liver cancer tissues in the example.
[0026] Figure 7 : This is the ROC curve of serum tRF-3a-Pro for liver cancer diagnosis in the example.
[0027] Figure 8 It is a schematic diagram of the technical route in the embodiment. DETAILED DESCRIPTION
[0028] The present invention is described in detail below in conjunction with specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, several variations and improvements may be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
[0029] Example 1
[0030] 1. Materials
[0031] 1.1 Clinical tissue specimens
[0032] The 33 clinical liver cancer tissue samples and their corresponding paracancerous tissues used in this example were all from liver cancer patients who underwent partial liver resection at Zhongshan Hospital Affiliated to Fudan University. After resection, the liver cancer / paracancerous tissues were washed with PBS and placed in an ice box for rapid processing in the laboratory; the tissues used for RNA extraction were divided into cryopreservation tubes, frozen in liquid nitrogen and stored in a -80°C refrigerator for use; the tissue samples used were confirmed by pathological examination for their properties, and were approved by the Ethics Committee of Zhongshan Hospital Affiliated to Fudan University, and all patients signed informed consent.
[0033] 1.2 Clinical serum specimens
[0034] This example included 122 patients with liver cancer, 59 patients with liver cirrhosis, and 50 healthy subjects from Zhongshan Hospital Affiliated to Fudan University. The inclusion and exclusion criteria were as follows:
[0035] (1) Common inclusion criteria
[0036] 1) Age ≥ 18 and ≤ 85 years old, regardless of gender;
[0037] 2) Received medical treatment or physical examination at Zhongshan Hospital Affiliated to Fudan University between January 2022 and January 2023;
[0038] 3) Have the ability to give informed consent and sign the informed consent form.
[0039] (2) Inclusion criteria for patients with liver cancer
[0040] 1) The postoperative liver pathology was diagnosed as liver cancer by two experienced pathologists;
[0041] 2) Patients with newly diagnosed tumors and no previous anti-tumor treatment (surgery, radiotherapy, chemotherapy, TACE, radiofrequency ablation, immunotherapy, etc.).
[0042] (3) Inclusion criteria for patients with cirrhosis
[0043] 1) Liver biopsy was diagnosed as cirrhosis by two experienced pathologists;
[0044] 2) If there is no histology, at least 2 imaging reports suggest cirrhosis (ultrasound, CT or MRI).
[0045] (4) Inclusion criteria for healthy controls
[0046] 1) Physical examination population of Zhongshan Hospital Affiliated to Fudan University;
[0047] 2) The patient has no underlying diseases except for stable hypertension and diabetes, and the physical examination results show that the patient is healthy.
[0048] (5) Common exclusion criteria
[0049] 1) Age <18 or >85 years old, regardless of gender;
[0050] 2) Patients with a history of other tumors besides liver cancer;
[0051] 3) The patient has other diseases that may affect this embodiment: including major cardiopulmonary diseases, immune system diseases, patients who need long-term hormone treatment due to other diseases, active bleeding, infection, etc.;
[0052] 4) Failure to obtain informed consent or sign the informed consent form.
[0053] This example includes 122 liver cancer patients, 59 liver cirrhosis patients, and 50 healthy people treated in Zhongshan Hospital of Fudan University from January 2022 to January 2023. The venous blood of all people was collected by serum separation tubes (yellow-headed tubes). After centrifugation at 3000rpm for 10 minutes, the supernatant was packaged and frozen in a -80℃ refrigerator for use. This example was approved by the Ethics Committee of Zhongshan Hospital of Fudan University, and all participants obtained informed consent. The design process is as follows Figure 8 shown.
[0054] 1.3 Primers and external references
[0055] The primers and external references in this example were synthesized by Shanghai Shenggong Biotechnology Co., Ltd.
[0056] 1.3.1 Reverse transcription primers
[0057] Table 1: Reverse transcription primer sequence information
[0058]
[0059] 1.3.2 qRT-PCR Primers
[0060] Table 2: qRT-PCR primer sequence information
[0061]
[0062] 1.3.3 External Reference
[0063] Table 3: External reference sequence information
[0064] name RNA sequence (5'-3') cel-mir-39 UCACCGGGUGUAAAUCAGCUUG
[0065] 1.4 Instruments
[0066] Table 4: Experimental instrument information
[0067] Instrument Name brand nation Micropipette ThermoFisher USA Benchtop centrifuge ThermoFisher USA Gradient PCR instrument Applied Biosystems USA Fluorescence quantitative PCR instrument Applied Biosystems USA Ultra-micro-spectrophotometer Nanodrop USA Ice Maker HOSHIZAKI Japan Electronic balance Flower Tide China -80℃ Refrigerator ThermoFisher USA Vortex mixer ThermoFisher USA
[0068] 1.5 Reagents and consumables
[0069] Table 5: Reagents and consumables information
[0070]
[0071]
[0072] 2. Methods
[0073] 2.1 Tissue RNA extraction
[0074] 1) Cut 50-100 mg of liver cancer or adjacent tissue frozen at -80°C on ice and transfer to a 1.5 mL RNase-free centrifuge tube. Add 1 mL TRIzol and quickly chop the tissue completely with ophthalmic scissors. Vortex thoroughly and let stand at room temperature for 5 minutes to lyse.
[0075] 2) Add chloroform to the centrifuge tube at a volume ratio of 5:1 between the above lysate and chloroform, vortex until an emulsion is formed, let stand at 25°C for 5 minutes, and then centrifuge at 12,000 g for 15 minutes at 4°C.
[0076] 3) The solution is now divided into three layers. Carefully transfer the upper aqueous phase to a new RNase-free centrifuge tube. Add an equal volume of isopropanol to the aqueous phase, invert to mix, and let settle at room temperature for 10 minutes. Centrifuge at 12000g at 4°C for 10 minutes.
[0077] 4) Discard the supernatant and retain the white precipitate at the bottom of the tube, add 1 mL of 75% ethanol to wash the precipitate, centrifuge at 12000g for 5 minutes at 4°C, carefully discard the supernatant and dry the precipitate in a fume hood at room temperature.
[0078] 5) After the precipitate is dried, an appropriate amount of RNase-free ddH2O is added to fully dissolve it and quantified using an ultra-micro spectrophotometer. If the A260 / A280 ratio is between 1.8 and 2.0, the RNA purity is qualified and then stored in a -80°C refrigerator for later use.
[0079] 2.2 Tissue tsRNA sequencing
[0080] Five clinical liver cancer tissue samples and their corresponding adjacent tissues were lysed and total RNA was extracted using TRIzol according to the above method. Subsequent library construction and tsRNA sequencing were completed by Shanghai Yunxu Biotechnology Co., Ltd. The process is briefly described as follows: RNA modification interference small RNA-seq library construction, first using rtStar TM tRF&tiRNA Pretreatment Kit was used to remove RNA modification, and small RNA library was constructed using The Small RNA Library Prep Kit (GenSeq, Inc.) was used for the amplified library. The products within the tsRNA length range were enriched by fragment screening, and then sequenced on the Illumina HiSeq sequencer. The original reads after sequencing were quality controlled, linker removed, and standardized to obtain the expression matrix. The subsequent analysis and mapping of differentially expressed tsRNA were completed with the help of R software.
[0081] 2.3 Extraction of tsRNA from serum
[0082] This experiment was performed according to the instructions of the small RNA extraction kit (DP501) of Tiangen Company. Before starting the experiment, the deproteinized solution MRD and the rinse solution RW were diluted to 1× with anhydrous ethanol.
[0083] 1) Take 500 μL of serum and add 500 μL of lysis buffer MZ, shake vigorously to mix, and lyse at room temperature for 5 minutes to separate the nucleic acid-protein complex.
[0084] 2) Centrifuge at 12000 rpm for 10 minutes at room temperature to remove protein precipitate, transfer the supernatant to another RNase free centrifuge tube, add 500 μL chloroform, shake vigorously for 15 seconds, let stand at room temperature for 5 minutes, and then centrifuge at 12000 rpm for 15 minutes.
[0085] 3) Measure the upper aqueous phase and transfer it to a new tube. Slowly add 1 / 3 of the volume of the above aqueous phase solution, anhydrous ethanol, mix well, add 20 fmol of external reference cel-mir-39, mix well, transfer to the adsorption column miRspin, leave at room temperature for 2 minutes, centrifuge at 12000 rpm for 30 seconds, and collect the effluent.
[0086] 4) Measure the volume of the effluent, slowly add 2 / 3 of the volume of anhydrous ethanol to mix well, and then transfer to the adsorption column miRelute. Leave it at room temperature for 2 minutes, centrifuge at 12000 rpm for 30 seconds at room temperature, discard the effluent, and retain the adsorption column miRelute.
[0087] 5) Wash the adsorption column miRelute once with 500 μL 1× deproteinization solution MRD at room temperature for 2 minutes, centrifuge at 12000 rpm for 30 seconds at room temperature, and discard the waste liquid.
[0088] 6) Wash the adsorption column miRelute twice with 500 μL 1× rinse solution RW at room temperature for 2 minutes, centrifuge at 12000 rpm for 30 seconds at room temperature, discard the waste liquid and centrifuge at 12000 rpm for 1 minute at room temperature, remove the residual liquid in the adsorption column and fully dry it.
[0089] 7) Transfer the adsorption column miRelute to a new RNase-Free 1.5mL centrifuge tube, add 20μL RNase-Free ddH2O, leave at room temperature for 2 minutes, centrifuge at 12000rpm for 1 minute at room temperature, and the eluate is the small RNA solution, which is stored in a -80℃ refrigerator for later use.
[0090] 2.4 Reverse transcription
[0091] In this embodiment, the reverse transcription experiment uses the ABScript II cDNA First-Strand Synthesis Kit from Ibotek, and the specific composition is shown in Table 6:
[0092] Table 6: Reverse transcription system composition
[0093] Components Dosage ABScript II Enzyme Mix (10×) 2μL ABScript II Reaction Mix (2×) 10μL dNTPs (10 mM each) 1μL Reverse transcription primer (10 μM) 1μL Total RNA / small RNA solution 1μg (tissue) / 5μL (serum) <![CDATA[RNase Free H2O]]> Make up to 20 μL
[0094] After completion, place it in the gradient PCR instrument and set the reverse transcription program as follows:
[0095] Table 7: Reverse transcription program settings
[0096] temperature time 42℃ 60 minutes 80℃ 5 minutes 4℃ ∞
[0097] After reverse transcription, the cDNA samples were stored in a -80°C refrigerator for later use.
[0098] 2.5 Real-time fluorescence quantitative PCR
[0099] In this example, the real-time fluorescence quantitative PCR experiment was performed using Yeason Hieff UniversalBlue qPCR SYBR Master Mix Kit, the specific composition is shown in Table 8:
[0100] Table 8: qRT-PCR system composition
[0101]
[0102] Three technical replicates were set for each sample, and the system was prepared in a 96-well PCR microplate and tested in a fluorescent quantitative PCR instrument. The reaction procedure is shown in Table 9:
[0103] Table 9: qRT-PCR program settings
[0104]
[0105] The tissue samples were treated with U6 as the internal reference and 2 -ΔΔCt The expression level of tsRNA was evaluated by the method. Where ΔCt = Ct (target tsRNA) - Ct (internal reference), ΔΔCt = ΔCtn - ΔCt1 (n is the tissue number). Serum samples used cel-mir-39 as an external reference and 2 -ΔΔCt The expression level of tsRNA was evaluated by the method, where ΔCt = Ct (target tsRNA) - Ct (external reference), ΔΔCt = ΔCtn - ΔCt1 (n is the serum number).
[0106] 2.6 Data Analysis
[0107] SPSS24.0, Prism 9.0, and R 4.2.0 were used for statistical analysis and drawing. The expression matrix of sequencing data was used to determine the source of tsRNA according to the tRNA sequence in the GtRNAdb database, and the tsRNA subclass was matched. The expression matrix after ID conversion was analyzed using the "edgeR" and "FactoMineR" packages, and the "ggplot2" package was used for drawing. For qRT-PCR data and clinical data of subjects, the Student t statistical method was used to test continuous variables, the chi-square test method was used to statistically analyze categorical variables, and the Pearson correlation coefficient was used to test the correlation between the two groups of data.
[0108] The receiver operating characteristic (ROC) curve was drawn and the area under the curve (AUC) was used to evaluate the diagnostic efficacy. The Youden index (sensitivity + specificity - 1) was used to calculate the cut-off value. The maximum Youden index was used to record the corresponding sensitivity and specificity. p < 0.05 was considered to be statistically significant, ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
[0109] result
[0110] 1. Analysis of differential tsRNA expression between liver cancer and adjacent tissues
[0111] To screen for abnormally expressed tsRNA in liver cancer, 5 pairs of liver cancer and adjacent tissue samples were collected for RNA extraction and tsRNA sequencing. Figure 1As shown in the figure, principal component analysis shows that the icons representing liver cancer (red) and adjacent tissues (blue) are clearly grouped, indicating that there are significant differences in tsRNA expression between liver cancer and adjacent tissues ( Figure 1 A). A total of 394 tsRNAs were detected in liver cancer tissues and adjacent tissues. Figure 1 B). With p<0.05 and log2|fold change|>1 as the boundary, after differential analysis, there were 26 up-regulated tsRNAs and 30 down-regulated tsRNAs in liver cancer tissues compared with adjacent adjacent tissues ( Figure 1 C).
[0112] In order to fully describe the tsRNA expression characteristics of liver cancer tissues, all tsRNA subclasses and source distributions obtained by high-throughput sequencing were analyzed. Figure 2 As shown. In both liver cancer tissue and adjacent paracancerous tissue, tRF-3a accounted for the highest proportion, followed by tiRNA-5 ( Figure 2 A, B). Among the tsRNAs with significantly different expressions, the upregulated tsRNA subtype in liver cancer tissues was mainly tRF-3a, while the downregulated tsRNA subtype was mainly tiRNA-5, indicating that the tRF-3a subtype may be a potential cancer-promoting tsRNA ( Figure 2 C, D). According to the classification of tsRNA source tRNA, in liver cancer tissue, the up-regulated tsRNA mainly comes from valine tRNA, and the down-regulated tsRNA mainly comes from glycine tRNA ( Figure 2 E, F).
[0113] 2. Proline tRNA-derived tRF-3a is highly expressed in tumor tissues and serum of patients with liver cancer
[0114] To further verify the differential expression of tsRNA in liver cancer and adjacent tissues, the top five tsRNAs upregulated in liver cancer tissues were selected (Table 10) and RNA extraction and qRT-PCR analysis were performed in 28 pairs of liver cancer and adjacent tissues. Figure 3 shown.
[0115] Table 10: Differential analysis of the top 5 tsRNAs upregulated in liver cancer tissues in sequencing data
[0116] tsRNA Log2FC p Value tRF-3a-Ala-AGC 10.11 0.0004 tRF-3a-Tyr-GTA 9.77 0.0014 tRF-3a-Pro-CGG 9.59 0.0034 tRF-3a-Ala-CGC 9.28 0.0061 tRF-2-Asn-GTT 9.03 0.0022
[0117] The results of qRT-PCR showed that the expression levels of the top four upregulated tsRNAs in the sequencing results: tRF-3a-Ala-AGC, tRF-3a-Tyr-GTA, tRF-3a-Pro-CGG, and tRF-3a-Ala-CGC in liver cancer tissues were significantly higher than those in adjacent tissues ( Figure 3A, B, C, D), the expression of tRF-2-Asn-GTT in liver cancer tissues was not significantly different from that in adjacent tissues ( Figure 3 E).
[0118] To explore whether tsRNA highly expressed in liver cancer tissues also has differential expression in serum, we first collected serum from 29 liver cancer patients, and collected serum from 16 cirrhotic patients and 17 healthy subjects as controls. We extracted small RNA from the serum and analyzed the data after qRT-PCR detection. Figure 4 Compared with the control group, the expression of tRF-3a-Pro-CGG in the serum of liver cancer patients was significantly increased ( Figure 4 A), but the levels of the other three tsRNAs: tRF-3a-Ala-AGC, tRF-3a-Tyr-GTA, and tRF-3a-Ala-CGC in the serum of patients with liver cancer did not increase significantly ( Figure 4 B, C, D).
[0119] Since each tsRNA sequence only corresponds to the first tRNA name matched in the GtRNAdb website when the sequencing data expression matrix is converted to an ID, it is not possible to determine whether a certain tsRNA is derived only from this tRNA. In addition to tRNA-Pro-CGG, tRNAs carrying proline also include tRNA-Pro-AGG and tRNA-Pro-UGG. Therefore, the sequence of tRF-3a-Pro-CGG was compared with the mature proline tRNA sequence in the GtRNAdb website, and it was found that the sequence of this tRF-3a is conserved in tRNAs carrying proline ( Figure 5 ). Therefore, tRF-3a-Pro-CGG (hereinafter referred to as tRF-3a-Pro) may be derived from a variety of proline tRNAs.
[0120] In addition, tumor tissues and paired serum samples from 14 patients were collected to detect whether there was a correlation between the tRF-3a-Pro content in the liver cancer tissue and serum of the same patient. The results showed that the expression of tRF-3a-Pro in serum was significantly positively correlated with the expression in paired liver cancer tissues (r=0.6433). Figure 6 ), indicating that patients with higher tRF-3a-Pro levels in liver cancer tissue also had higher tRF-3a-Pro levels in their serum, suggesting that tRF-3a-Pro in serum may be derived from tumor tissue.
[0121] 3. The diagnostic value of serum tRF-3a-Pro for liver cancer
[0122] tsRNA has the advantages of stable structure, conservative sequence and wide distribution, and is a potential biomarker. To evaluate whether there are differences in tRF-3a-Pro in the serum of patients with liver cancer, patients with cirrhosis and healthy controls, RNA extraction and detection were performed on the serum of 122 patients with liver cancer, 59 patients with cirrhosis and 50 healthy people who were treated in Zhongshan Hospital Affiliated to Fudan University from January 2022 to January 2023. The clinical characteristics of the subjects in each group are shown in Table 11.
[0123] Table 11: Clinical information of subjects
[0124]
[0125]
[0126] The serum small RNA of the above population was extracted and reverse transcribed, and after qPCR detection and data analysis, ΔCt = Ct (target tsRNA) - Ct (external reference), ΔΔCt = ΔCtn-7.86 (n is the serum number). The diagnostic threshold is: 1.4197, with 2 -ΔΔCt A value greater than 1.4197 was interpreted as positive, and the resulting AUC (95% CI) = 0.8616 (0.8143, 0.9090) ( Figure 7 ), and other diagnostic parameters are shown in Table 12.
[0127] Table 12: tRF-3a-Pro diagnostic parameters
[0128]
[0129] The above is a preferred embodiment of the present invention, but the present invention should not be limited to the contents disclosed in the embodiment. Therefore, any equivalent or modification completed without departing from the spirit disclosed in the present invention shall fall within the scope of protection of the present invention.
Claims
1. Use of a tsRNA biomarker for diagnosing hepatocellular carcinoma in the preparation of a product for diagnosing hepatocellular carcinoma, wherein the tsRNA biomarker is serum tRF-3a-Pro.
2. Use of a reagent for detecting a tsRNA biomarker in the preparation of a product for diagnosing hepatocellular carcinoma, wherein the tsRNA biomarker is serum tRF-3a-Pro.
3. The use according to claim 2, characterized in that: The reagent detects the expression level of tRF-3a-Pro in the serum of the subject. When the expression level of tRF-3a-Pro in the serum of the subject is high, it indicates a high risk of hepatocellular carcinoma.
4. The use according to claim 2, characterized in that: The product is a test kit.
5. The use according to claim 4, characterized in that: The kit is a real-time quantitative fluorescence PCR detection kit, which comprises a primer pair for detecting tRF-3a-Pro in serum, and the sequences are shown in SEQ ID NO: 1 and SEQ ID NO:
2.
6. The use according to claim 5, characterized in that: The kit detects the expression level of tRF-3a-Pro in the serum of a subject. When the expression level of tRF-3a-Pro in the serum of a subject is high, it indicates that the subject has a high risk of suffering from hepatocellular carcinoma.
